Even though management is saying the cancer trial was not a focus for them, it is never a good thing to have a failed trial.

Where we are moving to is taking an individual's cancer and measuring particular characteristics of it and saying, 'OK, you've got this wrong, this wrong and this wrong in your tumor and, therefore, I am going to treat you with Drug X, Drug Y and Drug Z because that is tailored to your cancer.'

Management is concerned about return on invested capital and return on shareholder equity and that's the focus. Everything else takes a backseat to that.

Focus on costs and asset management clearly remains the best course, given the fragile market conditions,

We believe we have the management, products and financial focus to foster long-term benefits for our shareholders and customers worldwide.

I'm glad to hear he's dropping it. Continued harassment of management would not have been good for keeping their focus on the business.